Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.

Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.

Item

http://www.wikidata.org/entity/Q37864722

Q37864722

about

Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer Focal therapy for localised prostate cancer: are we asking the correct research questions?Focal therapy for prostate cancer: rationale and treatment opportunities.Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.The role of focal therapy in the management of localised prostate cancer: a systematic review.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE").Preoperative prostate biopsy and multiparametric magnetic resonance imaging: reliability in detecting prostate cancer.Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy.Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.Positive surgical margins after minimally invasive radical prostatectomy in patients with pT2 and pT3a disease could be considered pathological upstaging.Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores.Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

P2860

Q26749961-DC620A48-CBAC-4729-AFA7-5A6B2B626CCC Q26822832-0A0D0796-8DC5-4F60-8C18-0C9B104EE631 Q26996937-2B17CEAD-0117-4B5A-B7B8-A2CB6A0481ED Q27692074-B4366F90-4AE3-4C47-B53F-42E4C7D0935D Q33702259-9A5871A8-1288-4340-BD35-8D9E47C063E9 Q34148722-1A2883DF-6668-4F80-B26C-60E290D2A6E0 Q34266167-524225AF-D98D-48BB-AC5F-AD35511ED6E0 Q35515150-1909CF7E-FA71-40D7-BF68-A8E0DBF5C091 Q37975227-785C0620-5BA6-4DD2-9B78-AAA11D926633 Q38026501-63D19E67-B1F0-41FA-B194-18964D87BB32 Q38193586-98478C99-48C5-4B57-AFAD-054805671200 Q38391587-6DC65D66-3626-4F78-898F-C9F8C4051CFC Q39041614-07339DFA-0A17-45E7-AAE6-B16D4A16A1A5 Q39572115-731795B5-CF83-4EA9-8C12-FC10898A1AC0 Q40211476-25565641-6688-414E-8A81-72B80904974B Q40358939-9C50B811-23DA-4007-98A5-ACD05D3C0058 Q40699570-FA2C126A-5ACF-4147-A723-6977A62D0D5E Q42366596-05986FDC-1BBB-4D02-8537-5D860ED2236B Q43589476-2E3FFB50-BC1E-49D2-8593-175B808574D8 Q43760304-D41F3D51-7491-47A7-BD2C-2720D2D1A7B9 Q47757923-DD167B11-6668-44A5-B0C2-B7F758A59A34 Q52916415-AC1754B6-D313-4BED-92C3-BF91ECA147A3

P2860

Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.

Item

http://www.wikidata.org/entity/Q37864722

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs